Note: Excerpted from Children's Health Defense. I took a look at the package insert for this new 6 in 1 vaccine called Vaxelis. Take a look at the contraindications for yourself.
Severe allergic reaction (e.g., anaphylaxis) to a previous dose of VAXELIS, any ingredient of VAXELIS, or any other diphtheria toxoid, tetanus toxoid, pertussis-containing vaccine, inactivated poliovirus vaccine, hepatitis B vaccine, or Haemophilus influenzae type b vaccine.(4.1) •Encephalopathy within 7 days of a previous pertussis-containing vaccine with no other identifiable cause. (4.2)•Progressive neurologic disorder until a treatment regimen has been established and the condition has stabilized.
How does one KNOW if one is going to have a severe allergic reaction if there is no test for who may be susceptible? This vaccine contains both yeast and soy. And Each 0.5 mL dose contains 319 mcg aluminum from aluminum salts used as adjuvants. There's an admission that pertussis vaccines can cause encephalopathy. "With no other identifiable cause,"? What doctor has ever said, "Oh! That's a vaccine injury, Mom." In fact, world "renowned" doctors testify in vaccine court on behalf of the pharma companies that this type of injury is so rare as to be negligible. Would autism be considered a progressive neurological disorder and what would doctors call a treatment regimen: early intervention??
A Six-in-One Vaccine Associated with Sudden Infant Death
The childhood vaccine schedule in the U.S. features numerous combination vaccines—formulations that bundle multiple antigens for multiple diseases into one injection. Examples of combination vaccines currently given to American children include Merck’s four-component ProQuad vaccine against measles, mumps, rubella and varicella and Sanofi’s five-in-one Pentacel vaccine against diphtheria, tetanus, pertussis, polio and Haemophilus influenzae type b.
The inclusion of Recombivax raises an instant red flag, given that it contains a problematic proprietary aluminum adjuvant possibly linked to serious autoimmune conditions.
Now, the U.S. is preparing to up the combination vaccine ante still further. At the close of 2018, the FDA approved the nation’s first six-in-one (hexavalent) vaccine—a Merck and Sanofi joint effort called Vaxelis intended for infants at ages two, four and six months. Like hexavalent vaccines given to infants in other countries, Vaxelis combines the five components featured in Pentacel along with Merck’s genetically engineered Recombivax vaccine against hepatitis B (HepB).
The inclusion of Recombivax raises an instant red flag, given that it contains a problematic proprietary aluminum adjuvant possibly linked to serious autoimmune conditions. In fact, when a Merck cyberattack in the summer of 2017 temporarily forced Recombivax out of the U.S. pediatric market and American children received GlaxoSmithKline’s HepB vaccine instead, annual reports of HepB vaccine-related deaths to the Vaccine Adverse Event Reporting System (VAERS) dropped by roughly 75% and injury reports halved. Read more at Children's Health Defense here.